Bluefin Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bluefin Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Hold	0	–	–	–	55
2022 Q2	–	Sell	-138,485	Closed	-$12.4M	–	760
2022 Q1	$12.4M	Sell	138,485 -38,257	-22%	-$3.53M	1.14%	12
2021 Q4	$19.8M	Sell	176,742 -58,024	-25%	-$7M	1.38%	17
2021 Q3	$29.5M	Buy	+234,766	New	+$30.2M	2.93%	6
2020 Q2	–	Sell	-113,853	Closed	-$8.82M	–	485
2020 Q1	$8.82M	Buy	+113,853	New	+$10.1M	1.14%	21

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bluefin Capital Management's XBI Position: Q1 2023 in Review

Bluefin Capital Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2023 at 0 shares worth $978K. The position accounts for 0.12% of the portfolio, ranked #55.

Bluefin Capital Management first reported a position in XBI in Q1 2020 and has held it in 4 quarters since. The position peaked at $29.5M in Q3 2021. 713 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

Bluefin Capital Management held 0 shares of State Street SPDR S&P Biotech ETF worth $978K as of Q1 2023.
Bluefin Capital Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2023.
State Street SPDR S&P Biotech ETF made up 0.12% of Bluefin Capital Management's portfolio in Q1 2023, its #55 holding.
Bluefin Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and has held it in 4 quarters since.
Bluefin Capital Management's State Street SPDR S&P Biotech ETF position peaked at $29.5M in Q3 2021.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Bluefin Capital Management's 13F filing for Q1 2023, filed 15 May 2023.